These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 24321371)

  • 1. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
    Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
    Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ; Huang C; Meng XM; Li J
    Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
    Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone acetylation is essential for ANG-II-induced IGF-IIR gene expression in H9c2 cardiomyoblast cells and pathologically hypertensive rat heart.
    Chu CH; Lo JF; Hu WS; Lu RB; Chang MH; Tsai FJ; Tsai CH; Weng YS; Tzang BS; Huang CY
    J Cell Physiol; 2012 Jan; 227(1):259-68. PubMed ID: 21412773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.
    Schuetze KB; McKinsey TA; Long CS
    J Mol Cell Cardiol; 2014 May; 70():100-7. PubMed ID: 24631770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium valproate ameliorates diabetes-induced fibrosis and renal damage by the inhibition of histone deacetylases in diabetic rat.
    Khan S; Jena G; Tikoo K
    Exp Mol Pathol; 2015 Apr; 98(2):230-9. PubMed ID: 25576297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
    Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
    Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
    Pang M; Zhuang S
    J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation.
    Olson EN; Backs J; McKinsey TA
    Novartis Found Symp; 2006; 274():3-12; discussion 13-9, 152-5, 272-6. PubMed ID: 17019803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
    Hamamori Y; Schneider MD
    J Clin Invest; 2003 Sep; 112(6):824-6. PubMed ID: 12975465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone deacetylases for heart failure.
    Bush EW; McKinsey TA
    Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
    Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
    Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
    Hess-Stumpp H
    Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of histone deacetylases (HDACs) in UPR regulation.
    Kahali S; Sarcar B; Chinnaiyan P
    Methods Enzymol; 2011; 490():159-74. PubMed ID: 21266250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of class II histone deacetylases.
    Fischle W; Kiermer V; Dequiedt F; Verdin E
    Biochem Cell Biol; 2001; 79(3):337-48. PubMed ID: 11467747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A role for histone deacetylases in the cellular and behavioral mechanisms underlying learning and memory.
    Mahgoub M; Monteggia LM
    Learn Mem; 2014 Oct; 21(10):564-8. PubMed ID: 25227251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.